Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …

The objective of this systematic review and meta-analysis was to assess and contrast the
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …

Objectives Bevacizumab and erlotinib inhibit different tumour growth pathways, and both
exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). However …

Background: Non-small cell lung cancer (NSCLC) has a poor prognosis despite
conventional treatments of surgery, radiotherapy, and chemotherapy. Small-molecule …

Objectives Combination treatment with erlotinib plus bevacizumab has the potential to
become a standard treatment regimen for patients with epidermal growth factor receptor …

Background In the phase II JO25567 study (JapicCTI‐111390), erlotinib plus bevacizumab
demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor …

Background Molecularly targeted agents for non-small cell lung cancer (NSCLC) can
provide similar efficacy to chemotherapy without chemotherapy-associated toxicities …

Introduction The introduction of epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) has improved the outlook for patients with advanced non-small-cell lung …

Purpose In this phase III clinical study, we assessed the clinical outcomes of combining
erlotinib with bevacizumab and panitumumab as second-line chemotherapy for patients with …

Background Bevacizumab and erlotinib target different tumour growth pathways with little
overlap in their toxic-effect profiles. On the basis of promising results from a phase 1/2 trial …